MYRON MAX LEVINE

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Vaccine development strategies for improving immunization: the role of modern immunology
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Nat Immunol 5:460-4. 2004
  2. pmc The Global Enteric Multicenter Study (GEMS): impetus, rationale, and genesis
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 55:S215-24. 2012
  3. pmc Factors that explain excretion of enteric pathogens by persons without diarrhea
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 55:S303-11. 2012
  4. doi request reprint "IDEAL" vaccines for resource poor settings
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Vaccine 29:D116-25. 2011
  5. ncbi request reprint Host-Salmonella interaction: human trials
    M M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore St, Baltimore, MD 21201, USA
    Microbes Infect 3:1271-9. 2001
  6. ncbi request reprint Enteric infections and the vaccines to counter them: future directions
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Vaccine 24:3865-73. 2006
  7. ncbi request reprint Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 45:S24-8. 2007
  8. pmc Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Nat Rev Microbiol 5:540-53. 2007
  9. doi request reprint Vaccines, global health and social equity
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Immunol Cell Biol 87:274-8. 2009
  10. pmc Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    BMC Biol 8:129. 2010

Detail Information

Publications52

  1. ncbi request reprint Vaccine development strategies for improving immunization: the role of modern immunology
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Nat Immunol 5:460-4. 2004
    ..An ideal vaccine has certain biological and physical characteristics. Technological advances have provided new strategies that may help the design of such a vaccine...
  2. pmc The Global Enteric Multicenter Study (GEMS): impetus, rationale, and genesis
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 55:S215-24. 2012
    ..GEMS data will guide investment and help prioritize strategies to mitigate the morbidity and mortality of pediatric diarrheal disease...
  3. pmc Factors that explain excretion of enteric pathogens by persons without diarrhea
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 55:S303-11. 2012
    ..Pathogens in stools of individuals without diarrhea may reflect recent ingestion of inocula too small to cause disease in otherwise susceptible hosts or of animal pathogens (eg, bovine or porcine ETEC) that do not cause human illness...
  4. doi request reprint "IDEAL" vaccines for resource poor settings
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Vaccine 29:D116-25. 2011
    ..Ideally, immunization would lead to a biomarker such as a specific vaccine-derived antibody that allows differentiation of successfully immunized persons from susceptibles...
  5. ncbi request reprint Host-Salmonella interaction: human trials
    M M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore St, Baltimore, MD 21201, USA
    Microbes Infect 3:1271-9. 2001
    ....
  6. ncbi request reprint Enteric infections and the vaccines to counter them: future directions
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Vaccine 24:3865-73. 2006
    ..Systematic implementation programs will have to be created in the least developed, high burden, high mortality countries to deliver enteric vaccines and to document their impact after introduction...
  7. ncbi request reprint Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 45:S24-8. 2007
    ..In the pooled analysis, Ty21a conferred significant protection against paratyphoid B fever (efficacy, 49%; 95% confidence interval, 8%-73%; P=.019)...
  8. pmc Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Nat Rev Microbiol 5:540-53. 2007
    ....
  9. doi request reprint Vaccines, global health and social equity
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Immunol Cell Biol 87:274-8. 2009
    ....
  10. pmc Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    BMC Biol 8:129. 2010
    ..The fundamental breakthrough is likely to require reversing effects of the 'environmental enteropathy' that is often present in children living in fecally contaminated, impoverished environments...
  11. ncbi request reprint Mass vaccination to control epidemic and endemic typhoid fever
    M M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
    Curr Top Microbiol Immunol 304:231-46. 2006
  12. pmc Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
    J Virol 77:5209-17. 2003
    ..flexneri can deliver measles DNA vaccines mucosally in cotton rats, inducing measles immune responses (including neutralizing antibodies) and protection, boosting strategies can now be evaluated in animals primed with MV DNA vaccines...
  13. pmc Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins
    Man Ki Song
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, 21201, USA
    J Virol 79:9854-61. 2005
    ..These data will help guide the design of DNA-based MV vaccines to be used early in life in a heterologous prime-boost strategy...
  14. ncbi request reprint Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy
    Christofer J Vindurampulle
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Vaccine 22:3744-50. 2004
    ..An ability to stimulate enhanced, accelerated responses to parenteral vaccination following mucosal priming may be advantageous in the immunoprophylaxis of many infectious diseases, including those of biodefense importance...
  15. ncbi request reprint Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA
    Rosângela Salerno-Goncalves
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Immunol 170:2734-41. 2003
    ....
  16. pmc Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909
    Rezwanul Wahid
    Center for Vaccine Development, Department of Pediatrics, University of Maryland, Baltimore, MD 21201, USA
    Vaccine 25:1416-25. 2007
    ..These observations add impetus for the continuing evaluation of CVD 909 as a typhoid vaccine candidate...
  17. pmc Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy
    Magaly Chinchilla
    Center for Vaccine Development, University of Maryland, 685 W Baltimore Street, HSF I, Room 480, Baltimore, MD 21201, USA
    Infect Immun 75:3769-79. 2007
    ....
  18. pmc Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain
    Zeev Altboum
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 71:1352-60. 2003
    ..These findings pave the way for CS4 to be included in multivalent ETEC vaccines, including an attenuated Shigella live-vector-based ETEC vaccine...
  19. pmc Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine
    James E Galen
    Center for Vaccine Development, Division of Geographic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Infect Dis 199:326-35. 2009
    ..In nonhuman primates, the success of this anthrax vaccine strategy based on heterologous mucosal priming followed by a parenteral subunit vaccine booster paves the way for clinical trials...
  20. pmc Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers
    Alejandra V E Capozzo
    Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore, 21201, USA
    Infect Immun 72:4637-46. 2004
    ..This is the first report that demonstrates the effectiveness of Salmonella live vector vaccines in early life...
  21. pmc PCR method to identify Salmonella enterica serovars Typhi, Paratyphi A, and Paratyphi B among Salmonella Isolates from the blood of patients with clinical enteric fever
    Haim Levy
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Clin Microbiol 46:1861-6. 2008
    ..quot; Blinded testing of 664 Malian and Chilean Salmonella blood isolates demonstrated 100% sensitivity and specificity...
  22. pmc Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes
    Araceli E Santiago
    Center for Vaccine Development, University of Maryland, Baltimore, 21201, United States
    Vaccine 27:2426-36. 2009
    ..These findings suggest the specific deletion of these target genes could generate a safe and efficacious live attenuated vaccine...
  23. ncbi request reprint Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies
    Alejandra V E Capozzo
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    J Immunol 176:5671-81. 2006
    ..Such a vaccine could be followed by the current live attenuated MV vaccine in a heterologous prime-boost to protect against measles early in life...
  24. ncbi request reprint Can needle-free administration of vaccines become the norm in global immunization?
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA mlevinemedicine umaryland edu
    Nat Med 9:99-103. 2003
  25. pmc A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors
    James E Galen
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore St, HSF Bldg I, Rm 480, Baltimore, MD 21201, USA
    Infect Immun 78:337-47. 2010
    ....
  26. pmc Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St, Room 480, Baltimore, Maryland 21201, USA
    J Virol 83:2789-94. 2009
    ..pMSIN-H priming conferred 100% protection against pulmonary measles, whereas pMSINH-FdU protected only in conjunction with the live measles virus vaccine boost...
  27. ncbi request reprint Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media
    Karen L Kotloff
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Hum Vaccin 3:268-75. 2007
    ....
  28. ncbi request reprint A case for immunization against nosocomial infections
    Alan S Cross
    Department of Medicine, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    J Leukoc Biol 83:483-8. 2008
    ..Such a strategy could reduce or ameliorate nosocomial infections and perhaps limit dissemination of nosocomial pathogens. Thus, a more aggressive effort to develop vaccines for nosocomial infections is warranted...
  29. pmc Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine
    Jakub K Simon
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA
    Clin Vaccine Immunol 18:355-61. 2011
    ....
  30. doi request reprint Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen
    Karina Ramirez
    Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Hum Gene Ther 19:522-31. 2008
    ..Both vaccines were shown to be well tolerated and suitable for clinical trials and they are currently being tested in phase 1 studies in young adults...
  31. pmc Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors
    Chee Mun Fang
    Department of Medicine, Division of Geographic Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 76:4422-30. 2008
    ..Furthermore, the success of the heterologous priming strategy supports the feasibility of the future development of multivalent live vector-based immunization strategies against multiple human pathogens...
  32. ncbi request reprint CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression
    Carol O Tacket
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Infect Dis 45:S20-3. 2007
    ..This review summarizes the clinical data that directed the logical progression of this vaccine development strategy...
  33. ncbi request reprint A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults
    Jakub K Simon
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Hum Vaccin 3:54-8. 2007
    ..Mucosal administration of currently licensed measles vaccine has been proposed to address issues of needle safety and improve vaccine uptake...
  34. ncbi request reprint Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants
    James D Campbell
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Pediatr Infect Dis J 21:822-6. 2002
    ....
  35. ncbi request reprint The causes of hospital admission and death among children in Bamako, Mali
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
    J Trop Pediatr 50:158-63. 2004
    ..Prospective surveillance using microbiological data is needed to delineate the organism-specific burdens...
  36. ncbi request reprint Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide
    Carol O Tacket
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 190:565-70. 2004
    ..Although many of the volunteers generated antibody-secreting cell responses to Vi, only 2 of the 32 volunteers generated anti-Vi IgG antibody in serum...
  37. ncbi request reprint Invasive pneumococcal infections among hospitalized children in Bamako, Mali
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD 21201, USA
    Pediatr Infect Dis J 23:642-9. 2004
    ..Prevention of invasive pneumococcal disease (IPD) in children is a global public health priority, and determination of the most common serotypes is crucial for vaccine development and implementation...
  38. ncbi request reprint Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208
    Karen L Kotloff
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 190:1745-54. 2004
    ....
  39. pmc Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA
    James E Galen
    Center for Vaccine Development, Separtmrnt of Medicine, School of Medicine, University of Maryland, 685 W Baltimore St, Baltimore, MD 21201, USA
    Infect Immun 72:7096-106. 2004
    ..0002). In addition, the induction of PA-specific gamma interferon and interleukin 5 responses was observed in splenocytes. This technology offers exceptional versatility for enhancing the immunogenicity of bacterial live-vector vaccines...
  40. ncbi request reprint A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali
    Milagritos D Tapia
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 73:26-31. 2005
    ..The early onset of the window of vulnerability in Kangaba infants likely reflects the changing ecology of measles in Africa. Ways to protect these vulnerable infants against measles must be devised...
  41. pmc Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults
    Karen L Kotloff
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 70:2016-21. 2002
    ..We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 10(3) to 10(6) CFU but elicits clinical reactions that must be assessed in further volunteer trials...
  42. ncbi request reprint Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model
    Eileen M Barry
    Center for Vaccine Development, University of Maryland, Baltimore, 685 West Baltimore Street, MD 21201, USA
    Vaccine 24:3727-34. 2006
    ..These studies demonstrate the potential of the use of mixtures of live Shigella derivatives expressing ETEC antigens to serve as an immunogenic multivalent vaccine...
  43. ncbi request reprint Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys
    Milagritos D Tapia
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Pediatr Infect Dis J 25:819-25. 2006
    ..Measurement of IgG tetanus antitoxin in oral fluid was investigated as a practical and noninvasive alternative to and correlate of serum antibodies...
  44. ncbi request reprint Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains
    Eileen M Barry
    Center for Vaccine Development, University of Maryland, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Vaccine 21:333-40. 2003
    ..Following mucosal immunization of guinea pigs with a mixed inoculum containing five Shigella strains each expressing a different ETEC antigen, immune responses were observed against each ETEC antigen plus the Shigella vector...
  45. ncbi request reprint Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Vaccine 21:401-18. 2003
    ..Typhi strains as vaccine candidates for the prevention of typhoid fever and as live vectors in humans...
  46. pmc Immunology of gut mucosal vaccines
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St, Room 480, Baltimore, MD 21201, USA
    Immunol Rev 239:125-48. 2011
    ..This review dissects the immune responses elicited in humans by enteric vaccines...
  47. pmc A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis)
    Steven T Shipley
    Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
    Comp Med 60:54-61. 2010
    ..We believe that this animal model may provide unique insights into the immunologic mechanisms of protection to S. dysenteriae 1 infection and in advancing development of a vaccine against shigellosis...
  48. pmc Salmonella enterica serovar Typhi live vector vaccines finally come of age
    James E Galen
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Immunol Cell Biol 87:400-12. 2009
    ..The time has now come for development of multivalent live vectors in which stable antigen expression and export is balanced with metabolic fitness to create highly immunogenic vaccines...
  49. ncbi request reprint Prevention of typhoid fever
    Myron M Levine
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Adv Exp Med Biol 568:161-73. 2005
  50. pmc Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali
    Sharon M Tennant
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    PLoS Negl Trop Dis 4:e621. 2010
    ..Importantly, including data from Mali, three serovars, Salmonella enterica serovar Typhimurium, Salmonella Enteritidis and Salmonella Dublin, account for the majority of non-typhoidal Salmonella isolated from these patients...
  51. ncbi request reprint Overview of vaccines and immunisation
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Br Med Bull 62:1-13. 2002
  52. ncbi request reprint Management of typhoid fever in children
    Ina Stephens
    Children s Hospital at Sinai and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Pediatr Infect Dis J 21:157-8. 2002

Research Grants33

  1. FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGY
    Myron Levine; Fiscal Year: 2007
    ..The ultimate goal of this training program is to provide a well-trained cadre of individuals who can fully exploit the unprecedented opportunities now available in vaccine development. ..
  2. RECOMBINANT & LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES
    Myron Levine; Fiscal Year: 2002
    ....
  3. BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA
    Myron Levine; Fiscal Year: 2004
    ..falciparum, and by these effects working in concert, we will ultimately be able to prevent disease completely in some subjects and to markedly ameliorate disease severity in others. ..
  4. RECOMBINANT & LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES
    Myron Levine; Fiscal Year: 2007
    ..abstract_text> ..
  5. Defense against Biowarfare and Emerging Infection Agents
    Myron Levine; Fiscal Year: 2007
    ..abstract_text> ..
  6. MULTIVALENT SALMONELLA TYPHI BASED MALARIA VACCINES
    Myron Levine; Fiscal Year: 1999
    ....
  7. RECOMBINANT AND LIVE ORAL SALMONELLA TYPHI VACCINES
    Myron Levine; Fiscal Year: 1993
    ..We will apply this information as we develop an S. typhi-based oral vaccine expressing diphtheria, tetanus and pertussis antigens...
  8. RECOMBINANT & LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES
    Myron Levine; Fiscal Year: 1992
    ..Hybrid constructs then will be used to provide information on the capacity of the carrier to elicit a broad range of immune responses against cloned antigens...